Search results
There are currently three IL-17 inhibitors approved by the FDA for forms of spondyloarthritis – specifically for ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and psoriatic arthritis (PsA).
Spondyloarthritis is a group of several related but distinct disorders: psoriatic arthritis, arthritis related to inflammatory bowel disease, reactive arthritis, a subgroup of juvenile idiopathic arthritis, and ankylosing spondylitis. Drugs used to treat Spondyloarthritis.
To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). We conducted updated systematic literature reviews for 20 clinical questions on ...
1 mar 2017 · This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE) guideline for the diagnosis and management of spondyloarthritis in people aged 16 years and above. 2 Recommendations and the clinical pathway are available via the NICE website.
Traditional or biologic DMARDs (disease-modifying anti-rheumatic drugs). Some specific types of spondyloarthritis, like psoriatic arthritis and enteropathic arthritis, have other treatments that specifically relate to the underlying condition (psoriasis or inflammatory bowel disease).
Introduction: The current pharmacological therapy of spondyloarthritis (SpA) includes several drugs: Non-steroidal anti-inflammatory drugs, corticosteroids, traditional disease-modifying antirheumatic drugs and biologic drugs.
Objective: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on ...
